- 专利标题: EXPRESSION OF FOXP3 IN EDITED CD34+ CELLS
-
申请号: US18336276申请日: 2023-06-16
-
公开(公告)号: US20240117352A1公开(公告)日: 2024-04-11
- 发明人: David J. Rawlings , Iram F. Khan , Yuchi Chiang Honaker , Swati Singh , Karen Sommer , Andrew M. Scharenberg
- 申请人: Seattle Children's Hospital (dba Seattle Children's Research Institute)
- 申请人地址: US WA Seattle
- 专利权人: Seattle Children's Hospital (dba Seattle Children's Research Institute)
- 当前专利权人: Seattle Children's Hospital (dba Seattle Children's Research Institute)
- 当前专利权人地址: US WA Seattle
- 主分类号: C12N15/113
- IPC分类号: C12N15/113 ; A61K35/15 ; C12N5/0783 ; C12N9/22
摘要:
Aspects of the invention described herein concern the incorporation of a FOXP3 cDNA (e.g., full-length human codon-optimized cDNA) into a FOXP3 gene or a non-FOXP3 locus so as to provide constitutive or regulated FOXP3 expression in a primary human CD34+ cells or cells derived from edited CD34+ cells. In some embodiments, guide RNA sequences that are directed to FOXP3, AAVS1, or other candidate loci are used for CRISPR/Cas9-mediated gene regulation, and gene delivery cassettes for HDR based gene-modification are provided.
信息查询
IPC分类: